Stock Analiz

Cryo Cell International Inc. CCEL

Misc Health and Biotechnology Services · IPO 2022 · data as of November 13, 2026

$4.85Market cap $39M
Open the interactive analysis →

Cryo Cell International Inc. (CCEL) is a healthcare company listed in the US with a market value of about $39M. In the twelve months to August 31, 2026 it had revenue of $31M and net income of -$2M, a net margin of -6.2%.

Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is shareholder returns (4/5); the weakest is value (1/5).

Key numbers: a price to free cash flow of 8.4, 5-year revenue growth of 0% a year, a 5-year average ROIC of 44%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 50% below the current price.

About Cryo Cell International

Cryo Cell International is listed in the US and classified in misc health and biotechnology services, IPO year 2022. Revenue went from $20M in 2014 to $32M in 2025, growth of about 4.2% a year. It was profitable in 6 of the last 10 years in our data. Its share count fell by 5% over three years (buybacks). It spends 1% of revenue on research and development.

Score: 1.8 / 5

Value1/5
Future growth1/5
Track record1/5
Financial health2/5
Shareholder returns4/5

Checks passed

  • P/FCF below 20
  • Profit margin improving
  • 5-year average ROIC above 12%
  • Positive free cash flow
  • Debt below 3 years of free cash flow
  • Pays a dividend
  • Share count down over 3 years (buybacks)
  • 20% to 100% of free cash flow returned to shareholders

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%

Valuation

P/E (TTM)—
Forward P/E—
P/FCF8.4
P/S1.3
P/B—
EV/EBITDA37.6
PEG—
Dividend yield0.00%
FCF yield11.9%
Shareholder yield0.4%
Intrinsic value vs. price−50%

Growth and quality

Revenue growth (1 yr)-1.3%
Revenue growth (5 yrs, per year)0.3%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-4.1%
ROIC (5-yr avg.)44.4%
Profitable years (of last 10)6
Years paying a dividend3

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$31M$32M$32M$31M$30M$29M$31M$32M$29M$25M$23M
Net income-$2M-$2M$402095-$10M$3M$2M$4M$2M-$854824$2M-$1M
Free cash flow$5M$5M$4M$2M-$4M$6M$8M$6M$5M$6M$5M
EPS (diluted)$-0.23$-0.30$0.05$-1.14$0.33$0.25$0.45$0.27$-0.11$0.30$-0.16
Net margin-6.2%-7.7%1.3%-30.4%9.1%7.2%11.6%7.2%-2.9%9.1%-5.7%
ROIC————43.0%45.8%154.1%170.7%101.6%——

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Cryo Cell International stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 50% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Cryo Cell International pay a dividend?

Not currently.

Is Cryo Cell International a good stock to buy?

We do not give buy or sell advice. Cryo Cell International scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.